Blog, News and Events

5 June 2024

Exhibition at the EASL Congress 2024

The European Association for the Study of the Liver (EASL) Congress 2024 presents a diverse scientific programme tailored to various specialties and levels of expertise in hepatology, including: metabolism, alcohol, toxicity; cirrhosis; liver tumors; viral hepatitis; general hepatology; and more! PhoenixBio is excited to be sponsoring a booth and attending the EASL Congress 2024 in person in Milan, Italy on June 5th - 8th, 2024. Meet with our team at Booth #O2 to learn more about PhoenixBio's capabilities and how we can help you advance and deliver tomorrow’s technologies.

Events

2 May 2024

Increasing translational potential with PXB-mice as an alternative to non-human primates

Non-human primates (NHPs) share a wide range of genetic and physiological features in common with humans. Yet, despite their widespread use in preclinical research, NHP models suffer from several limitations that can lead to a lack of translatability in clinical trials.

PXB-mouse, News, Blog

30 April 2024

Exhibition at the American Society of Cell & Gene Therapy 2024 Meeting

The American Society of Gene and Cell Therapy’s (ASGCT) Annual Meeting is the premier event for researchers in gene and cell therapy. The meeting will cover a range of topics from cutting-edge studies in cell and gene therapy, viral hepatitis, liver toxicity, MASH/MAFLD, and more. PhoenixBio is excited to be sponsoring a booth and attending ASGCT's 27th Annual Meeting in person at the Baltimore Convention Center in Baltimore, MD on May 7th - 11th, 2024. Meet with our team at Booth #1917 to learn more about PhoenixBio's capabilities and how we can help you advance and deliver tomorrow’s therapies.

Events

26 March 2024

Newsweek Feature: Pioneering Drug Development with Human Liver Models

Breaking News: Revolutionizing Pharmaceutical Innovation with Japan’s PhoenixBio In the realm of pharmaceutical innovation, a new dawn arises with Japan's PhoenixBio leading the charge. With a groundbreaking article recently published, PhoenixBio introduces cutting-edge human liver models boasting an astonishing 90% and higher human hepatocyte composition, redefining drug testing worldwide while upholding the highest ethical standards.

Press Releases, News

12 November 2023

American Association for the Study of Liver Diseases 2023 Meeting

Get ready to join the leading organization of scientists and healthcare professionals committed to preventing and curing liver disease! The Liver Meeting will cover a range of topics from cutting-edge studies in viral hepatitis, liver toxicity, gene therapy/editing, MASH/MAFLD, and more. PhoenixBio is delighted to be attending The Liver Meeting in person at the Hynes Convention Center in Boston, MA on November 11th - 13th, 2023. Meet with our team at Booth #1002 to learn more about PhoenixBio's capabilities and how we can help you advance and deliver tomorrow’s therapies.

Events

13 September 2023

2023 International HBV Meeting

PhoenixBio is delighted to be attending the International HBV Meeting in person at the Kobe International Conference Center in Kobe, Japan on September 19th - 23rd, 2023. We'll be sponsoring the conference and providing talks on preclinical models. Meet with our team to learn more about PhoenixBio's capabilities and how we can help you advance and deliver tomorrow’s therapies.

Events

13 September 2023

EuroTox 2023 Meeting

PhoenixBio is delighted to be attending the 57th Congress of the European Toxicologists and European Societies of Toxicology in person at the Ljubljana Exhibition and Convention Centre in Ljubljana, Slovenia on September 10th - 13th, 2023. We'll be exhibiting our products & services at booth #35. Meet with our team to learn more about PhoenixBio's capabilities and how we can help you with drug metabolism, pharmacokinetic, and toxicology research.

Exhibition, Events

21 August 2023

PXB-mouse: Overcoming species-to-species differences to accurately predict hepatotoxicity in therapeutic development

It is estimated that 40% of drug candidates have failed to make it to market because of toxicity.¹ One of the most common adverse drug reactions is drug-induced liver injury (DILI), whereby patients experience acute illness, often with symptoms similar to hepatitis and cholestasis. Today, DILI is the leading cause of drug candidate failure and post-market withdrawals.² The high incidence of DILI in clinical trials, and even post-market events, is partly due to the use of conventional animal models at preclinical stages. Conventional models are notoriously poor predictors of efficacy and toxicity in the liver, due to species-to-species variation. In contrast, the PXB-mouse® model, with its humanized liver, provides a highly predictive model of human physiology and human-specific hepatotoxicity, allowing for more accurate prediction of human outcomes, and, therefore, aiding the smooth progression of new therapeutics into the clinic.

PXB-mouse, News, Blog